How to Conduct Post-Market Surveillance for POCT Products After Overseas Registration?

Post-market surveillance (PMS) for POCT products after overseas registration is a core component of ongoing compliance. It involves target country regulatory requirements, product risk classification, technical file maintenance, adverse event reporting, change management, and certificate renewal. Manufacturers must first confirm whether their product falls under the scope of medical device regulations (e.g., US FDA CLIA classification, EU IVDR classification, China NMPA classification) and then determine specific PMS obligations based on risk level.

Key Summary

For GHWP member states (e.g., ASEAN countries, Saudi Arabia, Brazil), manufacturers are typically required to establish a PMS system that includes collecting user feedback, preparing Periodic Safety Update Reports (PSUR), adverse event reporting, recall management, label and instruction updates, and local agent coordination. Manufacturers may reuse processes from ISO 13485 such as CAPA, complaint handling, and internal audits, but must localize them for each country's regulations. For example, the EU requires a Post-Market Performance Follow-up (PMPF) plan, the US requires annual registration updates and MDR reports, and China requires periodic risk evaluation reports. Common risks include neglecting change notification, certificate interruption due to agent resignation, and failure to update technical files in a timely manner. Manufacturers should prepare a multi-country PMS documentation package in advance, designate an authorized representative, and conduct periodic mock regulatory inspections. This content is based on the AIMEILI Registration Practice Question Bank, Medical Device International Registration Knowledge Base, and publicly available regulatory information. Specific projects should be based on the latest requirements of target country regulatory authorities and product documentation.

Applicable Scenarios and Core Issues

After overseas registration of POCT products, the core issue manufacturers face is how to continuously meet regulatory requirements in the target market and avoid certificate suspension or revocation due to inadequate surveillance. PMS covers the entire product lifecycle from market launch to withdrawal, including adverse event reporting, change management, periodic updates, and market feedback collection. Regulatory requirements for PMS vary significantly: EU IVDR requires manufacturers to establish a PMS plan and submit PSUR; US FDA requires tracking of serious injury events through Manufacturer Reports (MDR); China NMPA requires post-market risk evaluation and annual reports. For manufacturers registering in multiple GHWP member states, a unified PMS system should be established that accommodates local language, reporting timelines, and agent responsibilities. A common misconception is that PMS is solely the responsibility of the quality department or focuses only on pre-certification document review. In reality, PMS is an extension of registration maintenance that directly affects certificate renewal and change approvals. For example, failure to update clinical evaluation conclusions in product labels and instructions could lead to market withdrawal risk. Therefore, manufacturers must integrate PMS into daily operations with clear division of responsibilities and resource allocation.

Registration Decision Logic

First, determine whether the product falls under the scope of medical device regulations in the target country. POCT products are mostly in vitro diagnostic reagents or devices, and classifications vary: EU IVDR divides into classes A, B, C, D; US FDA classifies based on CLIA complexity (Waived, Moderate, High Complexity); China classifies into three risk categories. Next, identify PMS obligations corresponding to the risk level: for example, EU Class C requires a PSUR submitted to a notified body, while Class D also requires post-market clinical follow-up. Then, assess whether the existing quality system (ISO 13485, MDSAP) covers core PMS activities such as complaint handling, adverse event reporting, and CAPA. If prior experience with CE or FDA registration exists, some PMS documents (e.g., PMS plan, PSUR template) can be reused, but format and content must be adjusted to local regulations. Finally, confirm the PMS responsibilities of the local agent or authorized representative, including assisting with adverse event reporting, communicating with regulators, and maintaining technical files. For multi-country registrations, it is recommended to select a third-party agency with multi-country qualification to centrally manage PMS affairs.

Documents and Evidence

Documents required for PMS can be categorized as follows:

• PMS Plan: Describes systematic activities including data collection methods, risk indicators, and evaluation cycles.
• PMS Report or PSUR: Periodically summarizes product safety and performance data. For EU Class C/D, PSUR submission is required.
• Adverse Event Reports: Reporting timelines vary by country (e.g., US: 30 days for serious injury, 5 days for death; EU: 2 days for serious public health threat).
• Complaint Handling Records: Include customer feedback, internal investigations, and CAPA closure.
• Change Management Documents: Changes in design, manufacturing process, labeling, or intended use must be evaluated for re-registration or notification.
• Certificate Maintenance Records: Such as FDA registration updates, EU CE certificate renewals, and updates to representative agreements in various countries.
• Market Monitoring Data: Feedback from distributors, customers, literature, and comparable products.

Manufacturers should retain original data for at least 5 years (EU requires at least 10 years from the end of the product lifecycle). Technical files must be kept updated; risk management reports and clinical evaluation reports should reflect new post-market information.

Common Mistakes

The most common issues manufacturers face include treating registration projects as simple document submissions without first clarifying product classification, evidence coverage, and local responsibility relationships. Other common errors include directly translating domestic NMPA documents without reorganizing evidence according to the target market pathway; having too many model numbers with insufficient test reports, clinical evidence, or labeling coverage; selecting a local agent solely based on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties; inconsistencies among labels, instructions, promotional materials, and registration documents leading to correction requests or post-market compliance risks; and failing to plan for multi-country document reuse, resulting in repeated work and increased cost and timelines for each country.

Company Preparation Checklist

• Establish a PMS management procedure defining departmental responsibilities and cross-department collaboration workflows.
• Designate a PMS manager who preferably possesses multi-country regulatory knowledge or works with external consultants.
• Develop PMS document templates (plan, report, record forms) adaptable to different regional requirements.
• Deploy data collection systems such as customer feedback platforms and adverse event tracking tools.
• Sign contracts with authorized representatives clearly specifying PMS responsibilities, and provide regular training.
• Create a change management flowchart distinguishing among changes requiring approval, notification, or only recording.
• Establish a certificate monitoring calendar initiating renewal procedures 6 months in advance.
• Conduct PMS internal audits semi-annually, referencing ISO 13485 and national regulations.

AIMEILI Perspective

The most underestimated aspect of POCT product PMS is change management. Many companies believe that functional improvements only need internal documentation but are unaware that under EU IVDR, any change affecting safety or performance may require notified body approval. In the early stages of a project, manufacturers should prioritize establishing a PMS plan rather than waiting until after registration. Core documents such as risk management files and clinical evaluation reports must be dynamically updated; they cannot be done once and left unchanged. Regarding reusability: complaint and CAPA records under ISO 13485 can be directly transferred, but report formats and submission methods must be localized, such as submission in Portuguese for Brazil. The local agent is not merely a nominal representative but should actively participate in PMS meetings and document reviews to avoid loss of certificate control due to agent inaction. For multi-country registrations, it is recommended to use international standards (e.g., ISO 14971, ISO 20416) to generate PMS data and then translate and output according to each country's requirements, which can significantly reduce duplicate work. Finally, certificate renewal is not an endpoint but the start of a new PMS cycle; manufacturers should view PMS as an investment in ongoing compliance.

Frequently Asked Questions

Q: What are the key PMS requirements for POCT products under EU IVDR?

A: EU IVDR requires manufacturers to implement PMS according to risk class. For Class C products, a PMS plan and PSUR (every 2 years or as needed) must be submitted to the notified body. Class D products additionally require post-market clinical follow-up (PMCF). Serious public health threats must be reported within 2 days, other serious incidents within 7 days, and deaths within 2 days. All reporting is done via the EUDAMED system.

Q: How can batch issues be managed uniformly when a product is registered in multiple GHWP member states?

A: It is recommended to establish a global product batch traceability system using a Unique Device Identifier (UDI) for cross-country recalls and notifications. The PMS documentation should include a comparison matrix of reporting contacts, timelines, and formats for each market. Periodically (e.g., quarterly) generate a global safety data summary and then break it down into reports required by each country. Use electronic platforms (e.g., locally deployed or cloud-based PMS software) to improve efficiency.

Q: With limited resources, how should a company prioritize post-market surveillance efforts?

A: For companies with limited resources, first ensure compliance for adverse event reporting and certificate maintenance. PMS report writing and regulatory communication can be outsourced to professional consulting firms. Domestic companies often neglect label and instruction updates; an annual review mechanism is recommended. Additionally, when signing service agreements with authorized representatives, clearly define their scope of responsibilities and response times to avoid violations due to agent delays.

Implementation Recommendations

In practice, companies should break down this issue into five tasks: regulatory determination, document preparation, evidence reuse, localization conversion, and post-market maintenance, rather than having only one department temporarily compile documents. This approach allows for earlier identification of document gaps and ensures that sales, R&D, quality, and regulatory teams have a consistent understanding of target country requirements. If a company plans to enter multiple markets simultaneously, it is advisable to first create a unified core technical file and then supplement authorization, labeling, language, forms, and local agent documents for each country. The efficiency of multi-country registration often depends on the consistency of the initial documentation framework rather than the submission speed for individual countries. First confirm whether the product falls under the scope of medical device regulations in the target country. Then confirm the risk class, registration pathway, and applicant entity. Verify that technical files, quality system, and clinical evidence support each other. Clarify the local agent, authorized representative, and certificate control. Establish post-market change, renewal, and vigilance event maintenance mechanisms.

This content is authored by the AIMEILI Regulatory Editorial Team and professionally reviewed by the AIMEILI Medical Device International Registration Project Team. Sources prioritize official regulatory bodies, international organizations, standard-setting organizations, and publicly available regulatory information; industry media and project experience are used only as supplementary reference. This document is intended for preliminary understanding, document preparation, and project planning and does not substitute for formal requirements, test conclusions, or legal advice from target country regulatory authorities.